Cargando…

Immunohistochemistry for c‐myc and bcl‐2 overexpression improves risk stratification in primary central nervous system lymphoma

Overexpression of bcl‐2 and c‐myc are defining features of double‐expressor‐lymphoma (DEL) but may also occur separately in patients with primary central nervous system lymphoma (PCNSL). Despite all progress in optimizing treatment regimen, there is lack of sufficient risk stratification models. Her...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatzl, Stefan, Posch, Florian, Deutsch, Alexander, Beham‐Schmid, Christine, Stöger, Herbert, Greinix, Hildegard, Pichler, Martin, Neumeister, Peter, Prochazka, Katharina T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496545/ https://www.ncbi.nlm.nih.gov/pubmed/32101329 http://dx.doi.org/10.1002/hon.2727

Ejemplares similares

Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective
por: Hatzl, Stefan, et al.
Publicado: (2021)

Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy
por: Hatzl, Stefan, et al.
Publicado: (2021)

Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival
por: Fechter, Karoline, et al.
Publicado: (2018)

Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas
por: Uhl, Barbara, et al.
Publicado: (2022)

NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
por: Prochazka, Katharina T, et al.
Publicado: (2016)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
por: Nwanze, Julum, et al.
Publicado: (2017)

Pathogen Detection by Metagenomic Next-Generation Sequencing During Neutropenic Fever in Patients With Hematological Malignancies
por: Schulz, Eduard, et al.
Publicado: (2022)

The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma
por: Troppan, K, et al.
Publicado: (2014)

The CXCR4–CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro
por: Pansy, Katrin, et al.
Publicado: (2019)

Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter’s Trans-Formed DLBCL and Germinal Center B-Cells
por: Uhl, Barbara, et al.
Publicado: (2022)

miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients
por: Troppan, Katharina, et al.
Publicado: (2015)

Risk stratification for febrile neutropenia in patients with testicular germ cell tumors
por: Terbuch, Angelika, et al.
Publicado: (2018)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions
por: Protrka, Z., et al.
Publicado: (2011)

Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer
por: Toon, Christopher W., et al.
Publicado: (2014)

Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas
por: Ohno, H, et al.
Publicado: (2017)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma
por: Wang, Jing, et al.
Publicado: (2015)

Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
por: Pansy, Katrin, et al.
Publicado: (2021)

Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study
por: Spindelboeck, Walter, et al.
Publicado: (2021)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type
por: Wang, Jing-hua, et al.
Publicado: (2017)

C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients
por: Troppan, K T, et al.
Publicado: (2014)

Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome
por: Unterluggauer, Julia J., et al.
Publicado: (2018)

A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2020)

Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study
por: Hatzl, Stefan, et al.
Publicado: (2021)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2
por: Mahadevan, Daruka, et al.
Publicado: (2014)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
por: Bellut, Julia, et al.
Publicado: (2017)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Frequent Down Regulation of the Tumor Suppressor Gene A20 in Multiple Myeloma
por: Troppan, Katharina, et al.
Publicado: (2015)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
por: Kim, Sehui, et al.
Publicado: (2016)

PB2157: TREATMENT WITH DIPHENYLENEIODONIUM CHLORIDE EXHIBITS CELL GROWTH INHIBITORY EFFECTS ON AGGRESSIVE LYMPHOMA CELLS
por: Haingartner, S., et al.
Publicado: (2022)

Response to “COVID-19 in persons with haematological cancers”
por: Hatzl, Stefan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a7t38l6g42r5ucscpvhj2g9tf0